Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 108.58M P/E - EPS this Y 1.10% Ern Qtrly Grth -
Income -53.93M Forward P/E -1.77 EPS next Y 19.40% 50D Avg Chg -7.00%
Sales 588k PEG -0.15 EPS past 5Y - 200D Avg Chg -9.00%
Dividend N/A Price/Book 0.97 EPS next 5Y 13.00% 52W High Chg -53.00%
Recommedations 2.00 Quick Ratio 5.44 Shares Outstanding 69.01M 52W Low Chg 29.00%
Insider Own 2.62% ROA -29.37% Shares Float 67.12M Beta 1.19
Inst Own 61.69% ROE -55.61% Shares Shorted/Prior 343.41K/383.05K Price 2.00
Gross Margin - Profit Margin - Avg. Volume 498,080 Target Price 24.60
Oper. Margin -7,079.15% Earnings Date Aug 7 Volume 336,694 Change 1.52%
About aTyr Pharma, Inc.

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

aTyr Pharma, Inc. News
06/05/24 Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
06/05/24 Timothy Coughlin Bought 833% More Shares In aTyr Pharma
06/03/24 aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
05/24/24 aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/15/24 aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
05/14/24 aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
05/06/24 aTyr Pharma to Present at Upcoming Investor Conferences
05/02/24 aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
04/21/24 aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k
04/01/24 aTyr Pharma to Participate in April Investor Conferences
03/26/24 3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
03/16/24 aTyr Pharma Full Year 2023 Earnings: Revenues Disappoint
03/15/24 aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript
03/15/24 Q4 2023 aTyr Pharma Inc Earnings Call
03/15/24 aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress
03/14/24 aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
02/28/24 aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
02/23/24 We Think aTyr Pharma (NASDAQ:LIFE) Can Afford To Drive Business Growth
02/21/24 aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
02/03/24 After losing 23% in the past year, aTyr Pharma, Inc. (NASDAQ:LIFE) institutional owners must be relieved by the recent gain
LIFE Chatroom

User Image 45IQ Posted - 13 hours ago


User Image Jscott76 Posted - 16 hours ago

$LIFE if we get any information on the EAP demand, that would help as well.

User Image StockTech7 Posted - 17 hours ago

$LIFE thinking this comes by start of Q4 - would be about 2-3 patients dosed per month. Data by H1 2025 or more likely Q2 2025. Earnigns reports talk of "big year for ATYR in 2025" that makes or breaks co. 👀

User Image StockTech7 Posted - 17 hours ago

$LIFE Patient page specifically lists September 2025 for topline data 👀 - https://atyrpharma.com/patients/clinical-trials/

User Image Southski Posted - 17 hours ago


User Image neverbeenwrong Posted - 1 day ago

$LIFE Company has cash through FDA approval.

User Image iTradeCallzNputz Posted - 1 day ago

$LIFE this will reverse split & do offering before heading anywhere

User Image jleelee Posted - 2 days ago

$LIFE what kind of catalyst are we waiting for?

User Image saitek88 Posted - 2 days ago

$LIFE $10 in 2025

User Image saitek88 Posted - 2 days ago

$LIFE Why the ticker symbol not $atyr? Anyway this is my LT investment, not a trade. 2025 will be the year for patient investors. $10+++

User Image OriginalTradeonrumor Posted - 2 days ago

$LIFE expected bounce as the small amount of retail that trades this ..some getting shook out this morning Tutes own close to 70% they control the ship ( especially during heavy volume days) Coming soon —>retest of 2-2.10 then a bounce down as swingers bail Then consolidation and eventual break out above 2.25 But congrats again to all longs …today’s milestone is huge (Watch for insider buys !)

User Image Stokwits Posted - 2 days ago

$LIFE Bags are a wee bit lighter. 🙂

User Image jacksparo Posted - 2 days ago

$LIFE Nice and bullish .

User Image jacksparo Posted - 2 days ago

$LIFE Great swing trade from my emails.

User Image StockTech7 Posted - 2 days ago

$LIFE muted reaction to the enrollment news - entering data desert

User Image OriginalTradeonrumor Posted - 2 days ago

$LIFE nice to see news out!! Huge milestone.

User Image Southski Posted - 2 days ago


User Image GO_Longs Posted - 2 days ago

$LIFE well Nevermind! Enrollment completed!!!

User Image GO_Longs Posted - 3 days ago

$LIFE as of 7/17/2024 the updated status of the study being reported to the clinical trials.gov site is that France, Germany, Italy, Netherlands, Spain, and United Kingdom are now also active and no longer recruiting along with the Japan sites which were the first to fully enroll patients. Seems like that have made a significant amount of progress since last update. Only sites left recruiting are in the U.S. and Brazil

User Image Altgeld_ATW Posted - 3 days ago

$life Any word on manufacturing EFZOFITIMOD?

User Image StockTech7 Posted - 3 days ago

$LIFE any guesses on when patient enrollment is completed for P2 Efzo-Connect? 25 patient target, first dosing started in October 2023, 28 week study. 👀

User Image Ms_P Posted - 6 days ago

$LIFE Now officially at the 2 week mark. Who bets they miss this?

User Image StockTech7 Posted - 6 days ago


User Image RallyRaider Posted - 6 days ago

$LIFE boring... in no mans land

User Image Ms_P Posted - 1 week ago

$LIFE How much do you think this will go up when end of enrollment is (finally) announced? It doesn’t seem to have gone up very much with last week on good news about interest rates potentially going lower.

User Image Southski Posted - 1 week ago


User Image OriginalTradeonrumor Posted - 1 week ago

$LIFE sometimes pictures speak louder than words PS—My gut says news this week

User Image Jscott76 Posted - 1 week ago

$LIFE building back up!!! Have a good weekend everyone!!

User Image neverbeenwrong Posted - 1 week ago

$LIFE $10 before $1

User Image StockTech7 Posted - 1 week ago

$LIFE dose the last patient

Analyst Ratings
HC Wainwright & Co. Buy May 14, 24
HC Wainwright& Co. Buy May 3, 24
RBC Capital Outperform Mar 15, 24
HC Wainwright & Co. Buy Mar 15, 24
HC Wainwright & Co. Buy Feb 21, 24
HC Wainwright & Co. Buy Sep 21, 23
HC Wainwright & Co. Buy Sep 14, 23
HC Wainwright & Co. Buy Aug 10, 23
Piper Sandler Overweight Jul 21, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Broadfoot Jill Marie Chief Financial Offi.. Chief Financial Officer Feb 05 Sell 1.69 1,590 2,687 20,821 02/06/24
SCHIMMEL PAUL Director Director May 10 Buy 2.25 200,000 450,000 313,023 05/11/23
Broadfoot Jill Marie Chief Financial Offi.. Chief Financial Officer Feb 03 Sell 2.36 1,566 3,696 15,460 02/06/23
Shukla Sanjay President and CEO President and CEO Nov 21 Buy 2.1405 10,000 21,405 50,798 11/21/22
Broadfoot Jill Marie Chief Financial Offi.. Chief Financial Officer Jan 13 Buy 6.75 1,923 12,980 12,112 01/18/22
Shukla Sanjay President and CEO President and CEO Jan 07 Buy 6.7613 5,000 33,806 25,798 01/10/22